ANIK — ANIKA THERAPEUTICS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
ANIK FAQ
What is ANIK's P/E ratio?
ANIKA THERAPEUTICS INC (ANIK) currently trades at a P/E ratio of 670.75.
What is ANIK's ROE?
ANIKA THERAPEUTICS INC reports a Return on Equity (ROE) of -8.26%.
What is ANIK's dividend yield?
ANIKA THERAPEUTICS INC offers a dividend yield of 0.00%.
What is ANIK's Deepscope Quality Score?
Deepscope rates ANIK's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ANIK?
Deepscope's AI Timing Score for ANIK is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ANIK belong to?
ANIKA THERAPEUTICS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 14.72
Price
0.00
(0.00%)
Day Change
|
|
|---|
ANIK Chất lượng tổng thể của cố phiếu Không tốt lắm ( Chất lượng = 54) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 14.72 |
| PBV / Sector |
1.46 / 2.65
GOOD
|
| Earning Per Share | -0.83 |
| PE / Sector |
670.75 / 24.99
|
| PEG or PE/Growth / Sector |
5.91 / 0.14
|
| Average 1M Daily Value |
0.99 M
GREAT
|
| Average 1W Daily Value |
0.96 M
GREAT
|
| Yếu tố Kỹ thuật |
|
42% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
56% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-13 11:13:05 |
| Symbol | ANIK |
| Name | ANIKA THERAPEUTICS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 13.31 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 195.86 / 10,015.19 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 32 Wiggins Avenue, Bedford, MA, United States, 01730
Phone: 781 457 9000
Website: https://www.anika.com
Employees: 235
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google